Daily notes / October 16, 2026

Yi Shi filed a Schedule 13G reporting an 11.1% Adarx stake

Written by a model from the facts OQRO holds and checked against them, sentence by sentence of October 16, 2026. Published October 18, 2026. 2 min read.

Tall office buildings around Trinity Church in lower Manhattan seen from above, with the church spire between the towers. — Skyscrapers around Trinity Church, New York, 1905. Photo: Detroit Publishing Company (scan by the New York Public Library), Public domain (scan of a 1905 photograph, New York Public Library Digital Collections). Original

The short answer

Yi Shi filed a Schedule 13G on Oct 16, 2026, reporting 11,858,655 shares, or 11.1% of the class of Adarx Pharmaceuticals (ADRX). The filing records an ownership position, not when shares were bought. Other public records include a separate Adarx ownership filing, a company Form 8-K, clinical-trial updates and share-price data.

What did Yi Shi report in the filing?

The SEC Schedule 13G filed on Oct 16, 2026 reports that Yi Shi held 11,858,655 shares, representing 11.1% of the class of Adarx Pharmaceuticals (ADRX).

A Schedule 13G is an ownership filing, not a report of a trade. The filing does not say when the shares were bought.

What other ownership filing is on record?

In the 180 days to Oct 16, 2026, SR One Capital Management, LLC disclosed a 9.3% stake in ADRX. That Schedule 13D and 13G filing was filed Oct 5, 2026.

The separate disclosure provides additional public ownership context. It does not change what Yi Shi reported in the Schedule 13G.

What company filings and trial updates are on record?

Adarx Pharmaceuticals filed a Form 8-K on Sep 28, 2026, 2 days before the Schedule 13G. OQRO classifies the filing as reporting that the company sold new shares without registering them and changed its bylaws, charter or fiscal year, and 1 more item.

ClinicalTrials.gov shows 5 studys sponsored by the company updated in the period. The latest, STOP-HAE: A Phase 3 Study of ADX-324, is listed as Phase 3 and recruiting. It was updated on Sep 10, 2026, with primary completion listed for 2027-11-30.

How did ADRX shares move around the filing?

ADRX closed at $19.94 on Sep 30, 2026, the last session on or before the filing date. From Sep 25, 2026 to Sep 30, 2026, the close moved from $19.35 to $19.94, a change of +3.0%.

From Sep 30, 2026 to Oct 16, 2026, the close moved from $19.94 to $17.65, a change of −11.5%. These price moves are context only; the filing does not explain them, and other news can move a price.

What else does public market data show?

FINRA short interest for ADRX on the settlement date of Sep 30, 2026 was 1,163,375 shares, +100% on the previous report, or about 1.74 days of average volume.

The Adarx Pharmaceuticals page on OQRO provides company context alongside public filings and market records. Short-interest data and share-price movements do not establish when Yi Shi acquired shares or explain the reported ownership position.

What this does not tell you?

The Schedule 13G does not say when shares were bought. The Form 8-K reports what the company disclosed, not what that disclosure means for the share price.

The listed price moves are context only; the filing does not explain them, and other news can move a price. This article describes public filings and is not investment advice.

Sources

A model wrote this page from the facts OQRO holds; every number, date, name and link in it was checked against those facts before publication, and a text that failed the check was not published. It describes what was filed, not why, and it is not investment advice. How OQRO treats data